The recently concluded India-European Union Free Trade Agreement (FTA) is poised to deliver a substantial boost to India’s pharmaceuticals and medical technology industries by opening access to the EU’s $572.3 billion pharmaceuticals and medical devices market one of the largest markets of its kind globally.

Government and industry sources say the agreement will enhance export opportunities, scale up market reach and strengthen India’s role as a global supplier of affordable medicines and health technologies.

Under the new trade framework, tariffs on a wide range of pharma and medtech products are being reduced or phased out, offering near-zero duty access to European markets and improving competitiveness for Indian manufacturers. While Indian generic drugs historically entered the EU duty-free, the FTA’s preferential terms and deeper market integration are expected to benefit bulk drugs (APIs), formulations and complex therapeutics as well as medical devices and surgical equipment.

Industry analysts highlight that the agreement’s tariff cuts including elimination of duties of up to 11 per cent on pharmaceuticals and up to nearly 28 per cent on medical devices will strengthen Indian firms’ cost position and make high-quality products more price-competitive in Europe’s highly regulated markets. Indian exporters already serve about 19 per cent of their pharma export markets in the EU, but the FTA can accelerate growth across high-value segments such as biosimilars and specialty drugs.

Beyond tariffs, the deal also addresses non-tariff barriers and regulatory cooperation, which are critical in healthcare product trade. Improved transparency, customs facilitation and steps toward regulatory alignment are expected to reduce compliance costs, shorten market entry timelines and help smaller manufacturers participate more actively in exports. Experts believe that these structural improvements could drive employment growth, encourage investment in manufacturing capacity and support micro, small and medium enterprises (MSMEs) within India’s pharma ecosystem.

The agreement may also lower drug and medical equipment costs for Indian consumers over time as imported inputs and advanced technologies become more affordable. This includes specialised imaging equipment, diagnostic devices and high-end therapeutics that currently attract higher duties and regulatory costs. European firms may also expand their investment in India’s research-based pharmaceutical and medtech sectors, fostering deeper innovation collaboration.

This could accelerate innovation across biopharma, biosimilars, advanced medical technologies and digital health solutions, reinforcing India’s growing international stature in healthcare manufacturing and exports.

As the pact moves toward ratification by the European Parliament, EU member states and India’s Cabinet, stakeholders are preparing for phased implementation that could reshape global healthcare trade, strengthen supply chains and support affordable access to quality treatments worldwide.